New to peptides? Start with the foundations ->
The dad-test answer
Cerebrolysin is a porcine-brain peptide cocktail used as a 21-day infusion course for ischemic stroke and TBI, with the CARS and CAPTAIN trial signal behind it. CDP-choline (citicoline) is an oral choline donor with a long Spanish/European trial record for cognitive decline and stroke recovery. Cerebrolysin is the heavier intervention with a stronger acute-stroke signal; citicoline is the daily oral with deeper safety data and easier access.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| early-window ischemic stroke recovery |
cerebrolysin CARS trial (Muresanu et al., Stroke 2016) showed motor function recovery benefit when given within 72 hours as a 21-day infusion. |
| long-term cognitive support, post-stroke decline |
cdp-choline Multiple long-duration trials show citicoline prevents post-stroke cognitive decline; oral 500-2000mg/day protocols are well tolerated for months. |
| delivery, access, daily use |
cdp-choline Oral capsule sold as a supplement in the US; cerebrolysin requires IV/IM infusion course at a clinic. |
| depth of mechanism |
cerebrolysin Multi-component peptide cocktail with neurotrophic, antioxidant, and anti-inflammatory mechanisms; citicoline is a single-pathway choline donor. |
What the head-to-head data shows
CDP-choline (citicoline) is not a peptide - it's an intermediate in phosphatidylcholine synthesis that donates choline and cytidine to neuronal membranes. We cover it because patients with stroke or cognitive decline ask about both. The cerebrolysin signal sits on Muresanu et al., Stroke 2016 (CARS trial) - 208 patients with acute ischemic stroke, 21-day infusion within 72 hours of onset, improved Fugl-Meyer Assessment vs placebo at 90 days. Heiss et al., J Stroke Cerebrovasc Dis 2012 (CAPTAIN II) replicated the signal. The citicoline evidence is broader and more mixed - Clark et al., Stroke 1999 and the ICTUS trial (Davalos et al., Lancet 2012) showed mixed signals in acute stroke; the long-term post-stroke cognitive decline data is more positive. Secades 2015 reviews the full citicoline record. Neither carries a strong AHA/ASA guideline recommendation; both sit at Class III Level A in 2026 stroke guidelines.
Our honest call
These solve different problems. For an acute ischemic stroke or major TBI, cerebrolysin is the molecule with the cleaner trial signal and a 21-day infusion course is the protocol that the trials used - this is a clinical decision made with a neurologist, not a daily supplement choice. For long-running cognitive support, citicoline is the easier protocol - oral capsules at 500-1000mg/day, real safety data, available as a supplement in the US, used for years in European practice. Most aggressive operators run citicoline daily and reserve cerebrolysin for an acute event or a structured 21-day boost. The cerebrolysin stroke recovery protocol covers the acute path.
Sources and citations
- Muresanu et al., CARS trial cerebrolysin in early stroke, Stroke 2016 (PMID 27365443)
- Heiss et al., CAPTAIN II cerebrolysin trial, J Stroke Cerebrovasc Dis 2012 (PMID 22261736)
- Clark et al., Citicoline in acute ischemic stroke, Stroke 1999 (PMID 10582987)
- Davalos et al., ICTUS trial citicoline in stroke, Lancet 2012 (PMID 22877718)
- Secades, Citicoline review, Rev Neurol 2015
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.